Till Örebro universitet

oru.seÖrebro universitets publikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The Determination of Diabetes Utilities, Costs, and Effects Model: A Cost-Utility Tool Using Patient-Level Microsimulation to Evaluate Sensor-Based Glucose Monitoring Systems in Type 1 and Type 2 Diabetes: Comparative Validation
EVERSANA, Burlington ON, Canada.
ESSEC Business School, Cergy, France.
Ben-Gurion University of the Negev, Be'er Sheva, Israel.
University of Western Ontario, London ON, Canada.
Visa övriga samt affilieringar
2024 (Engelska)Ingår i: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 27, nr 4, s. 500-507Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

OBJECTIVE: To assess the accuracy and validity of the DEtermination of Diabetes Utilities, Costs, and Effects (DEDUCE) model, a Microsoft Excel-based tool for evaluating diabetes interventions for type 1 and type 2 diabetes.

RESEARCH DESIGN AND METHODS: The DEDUCE model is a patient-level microsimulation, with complications predicted based on the Sheffield and RECODe diabetes models for type 1 and type 2 diabetes, respectively. For this tool to be useful, it must be validated to ensure that its complication predictions are accurate. Internal, external and cross validation was assessed by populating the DEDUCE model with the baseline characteristics and treatment effects reported in clinical trials used in the Fourth, Fifth, and Ninth Mount Hood Diabetes Challenges. Results from the DEDUCE model were evaluated against clinical results and previously validated models via mean absolute percentage error (MAPE) or percentage error.

RESULTS: The DEDUCE model performed favorably, predicting key outcomes including cardiovascular disease in type 1 diabetes and all-cause mortality in type 2 diabetes. The model performed well against other models. In the Mount Hood 9 Challenge comparison, error was below the mean reported from comparator models for several outcomes, particularly for hazard ratios.

CONCLUSIONS: The DEDUCE model predicts diabetes-related complications from trials and studies well when compared to previously validated models. The model may serve as a useful tool for evaluating the cost-effectiveness of diabetes technologies.

Ort, förlag, år, upplaga, sidor
Elsevier, 2024. Vol. 27, nr 4, s. 500-507
Nyckelord [en]
DEDUCE Model, Patient-Level Microsimulation, Sensor-Based Glucose Monitoring Systems
Nationell ämneskategori
Endokrinologi och diabetes
Identifikatorer
URN: urn:nbn:se:oru:diva-111379DOI: 10.1016/j.jval.2024.01.010ISI: 001221752200001PubMedID: 38307388Scopus ID: 2-s2.0-85186212529OAI: oai:DiVA.org:oru-111379DiVA, id: diva2:1834569
Anmärkning

This study was supported by Abbott Diabetes Care (ADC).

Tillgänglig från: 2024-02-05 Skapad: 2024-02-05 Senast uppdaterad: 2024-05-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Jendle, Johan

Sök vidare i DiVA

Av författaren/redaktören
Jendle, Johan
Av organisationen
Institutionen för medicinska vetenskaper
I samma tidskrift
Value in Health
Endokrinologi och diabetes

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 50 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf